Our Pricing

Best Price Wegovy - Use Code WEIGHTLOSSNEW for £79.00

Published on: June 03, 2026

Searching for the best price Wegovy UK online with genuine savings? At Cured Pharmacy, you'll access UK-licensed Wegovy (semaglutide) pens from £79.00 using code WEIGHTLOSSNEW—backed by our lowest prices guarantee, free clinical consultation with UK prescribers, and 100% discreet packaging. Every prescription requires clinical assessment to ensure suitability and safety.

How Wegovy Delivers Clinically Proven Weight Loss

Wegovy contains semaglutide, a GLP-1 receptor agonist licensed by the MHRA for chronic weight management in adults with a BMI of 30 kg/m² or above, or 27 kg/m² with at least one weight-related comorbidity [1]. Semaglutide mimics the natural hormone GLP-1, slowing gastric emptying, reducing appetite, and improving glycaemic control—mechanisms that work synergistically to support sustained weight reduction.

In the landmark STEP 1 trial involving 1,961 participants, those receiving once-weekly semaglutide 2.4mg achieved an average body weight reduction of 14.9% over 68 weeks, compared to 2.4% with placebo [1]. Importantly, 86.4% of participants on semaglutide lost at least 5% of their baseline body weight, and more than half lost 15% or more [1]. These results represent some of the most substantial weight loss outcomes observed in pharmacological trials to date.

Beyond weight reduction, clinical data shows semaglutide may improve cardiovascular risk markers, including reductions in waist circumference, systolic blood pressure, and HbA1c in patients with prediabetes [2]. At Cured Pharmacy, our UK-registered clinical team assesses your medical history, current medications, and weight loss goals during a free online consultation to determine whether Wegovy is appropriate for you.

Best Price Wegovy UK: Transparent Pricing Before Consultation

One of the most frustrating aspects of online pharmacy shopping is hidden pricing—being asked to complete a lengthy consultation before discovering the actual cost. At Cured Pharmacy, we believe in transparent upfront pricing. You'll see the cost of Wegovy (from £79.00 with code WEIGHTLOSSNEW) before you start your clinical assessment, allowing you to make an informed decision without wasting time.

Our pricing model reflects our commitment to offering the lowest prices guaranteed across the UK market. We source genuine UK-licensed medicines directly and pass savings directly to patients. Unlike some providers who inflate baseline prices before applying discount codes, our everyday pricing is competitive from the outset—and our promotional codes deliver real, meaningful savings.

All Wegovy pens dispensed by Cured Pharmacy are sourced through licensed UK wholesalers and stored in our GPhC-registered premises (Registration Number 9012511) under the supervision of our superintendent pharmacist, Tarun Kumar (GPhC 2233073). You receive the same pharmaceutical-grade semaglutide prescribed through traditional high-street pharmacies, but with the convenience of online ordering and discreet home delivery.

What's Included in Your Wegovy Service

When you order Wegovy through Cured Pharmacy, the service includes a comprehensive clinical consultation with a UK-registered prescriber (typically completed in under 3 minutes), your prescribed Wegovy pens delivered in discreet, unmarked packaging, ongoing support from our pharmacy team via phone or email, and access to dose escalation guidance as you progress through the treatment schedule. Your prescription is reviewed by our clinical team to ensure it aligns with MHRA-approved dosing protocols and your individual health profile.

Understanding Wegovy Dosing and Treatment Timeline

Wegovy follows a structured dose escalation schedule designed to minimise gastrointestinal side effects while optimising therapeutic efficacy. Treatment begins with a 0.25mg once-weekly injection for the first four weeks, then increases monthly through 0.5mg, 1mg, and 1.7mg doses before reaching the maintenance dose of 2.4mg at week 17 [3].

This gradual titration allows your body to adapt to semaglutide's effects on gastric emptying and satiety signalling. Clinical trials demonstrate that patients who follow the recommended escalation schedule experience fewer discontinuations due to nausea, vomiting, or diarrhoea compared to those who attempt faster dose increases [3]. Our UK prescribers assess your tolerance at each stage and may adjust the timeline if you experience persistent side effects.

Most patients begin noticing appetite suppression within the first two weeks of treatment, though significant weight loss typically becomes apparent after reaching higher doses. The STEP trials measured outcomes at 68 weeks, reflecting the fact that Wegovy is designed for long-term weight management rather than rapid short-term results [1]. Sustainable weight loss requires behavioural changes alongside pharmacotherapy—our clinical team can provide guidance on nutrition and physical activity strategies that complement your treatment.

Injection Technique and Storage

Wegovy is administered subcutaneously (under the skin) once weekly, on the same day each week, in the abdomen, thigh, or upper arm. The pre-filled pens are designed for ease of use, with clear dosing windows and simple injection mechanisms. Pens should be stored in a refrigerator between 2°C and 8°C until first use, and can then be kept at room temperature (below 30°C) for up to 28 days. Always inspect the solution before injecting—it should be clear and colourless. If you notice particles or discolouration, do not use the pen and contact our pharmacy team for a replacement.

Wegovy vs Other Weight Loss Treatments: Clinical Comparison

The UK weight loss treatment landscape now includes several prescription options, each with distinct mechanisms, efficacy profiles, and cost considerations. Understanding these differences helps you and your prescriber select the most appropriate therapy for your circumstances.

Semaglutide (Wegovy) and tirzepatide represent the newest generation of GLP-1 receptor agonists, demonstrating superior weight loss compared to older agents like liraglutide or orlistat. Tirzepatide, a dual GIP/GLP-1 receptor agonist, showed average weight reductions of 20.9% at the highest dose in the SURMOUNT-1 trial—numerically higher than semaglutide's 14.9% in STEP 1, though head-to-head trials are limited [4][1].

Oral medications like orlistat work through a completely different mechanism—blocking dietary fat absorption in the intestine—and typically produce more modest weight loss (average 3-5% body weight reduction) with gastrointestinal side effects related to fat malabsorption [5]. Orlistat may be suitable for patients who prefer oral therapy or have contraindications to injectable treatments, but the clinical data clearly demonstrates greater efficacy with GLP-1 therapies for most patients.

Your UK prescriber will consider your BMI, weight loss goals, medical history (including cardiovascular disease, type 2 diabetes, or thyroid conditions), previous treatment responses, and personal preferences when recommending a specific agent. All prescription weight loss medications require ongoing lifestyle modification—including reduced caloric intake and increased physical activity—to achieve optimal results.

Common Side Effects and How to Manage Them

The most frequently reported side effects of Wegovy are gastrointestinal: nausea (44% of patients in clinical trials), diarrhoea (30%), vomiting (24%), constipation (24%), and abdominal pain (20%) [3]. These effects are typically mild to moderate in severity and tend to diminish as your body adapts to the medication, particularly if you follow the recommended dose escalation schedule.

Practical strategies to minimise GI side effects include eating smaller, more frequent meals rather than large portions; avoiding high-fat, greasy, or heavily spiced foods; staying well-hydrated throughout the day; and injecting Wegovy at a consistent time when you can manage potential nausea (many patients prefer evening injections). If you experience persistent vomiting or signs of dehydration, contact our pharmacy team or your GP immediately.

Serious but rare adverse events include pancreatitis (inflammation of the pancreas), gallbladder disease, and hypoglycaemia in patients taking concurrent diabetes medications [3]. Wegovy carries a boxed warning regarding thyroid C-cell tumours observed in rodent studies, and is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 [3]. Our UK prescribers screen for these contraindications during your clinical assessment to ensure safe prescribing.

When to Seek Medical Advice

Contact a healthcare professional immediately if you experience severe abdominal pain (which may radiate to your back and could indicate pancreatitis), persistent vomiting leading to dehydration, visual changes, signs of allergic reaction including rash or difficulty breathing, or symptoms of hypoglycaemia such as shakiness, confusion, or rapid heartbeat. Our pharmacy team is available on (+44) 116 4646009 during business hours, and you should contact NHS 111 or attend A&E for urgent concerns outside these times.

Who Can Use Wegovy: Eligibility and Contraindications

Wegovy is licensed in the UK for adults with an initial BMI of 30 kg/m² or greater (obesity), or 27 kg/m² or greater (overweight) in the presence of at least one weight-related comorbid condition such as hypertension, type 2 diabetes, dyslipidaemia, or obstructive sleep apnoea [3]. NICE guidance recommends considering GLP-1 therapies as part of a specialist weight management service for patients who meet these criteria and have not achieved adequate weight loss through lifestyle interventions alone.

Wegovy is contraindicated in patients with a personal or family history of medullary thyroid carcinoma, Multiple Endocrine Neoplasia syndrome type 2, or a history of serious hypersensitivity to semaglutide or any excipients [3]. It should be used with caution in patients with a history of pancreatitis, severe gastrointestinal disease, renal impairment, or diabetic retinopathy. Wegovy is not recommended during pregnancy or breastfeeding, and women of childbearing potential should use effective contraception during treatment.

During your free online consultation at Cured Pharmacy, our UK prescribers will review your complete medical history, current medications (including over-the-counter and herbal supplements), allergies, and any previous weight loss attempts. This assessment ensures Wegovy is both safe and appropriate for your individual circumstances. If our clinical team determines an alternative treatment would be more suitable, they will discuss other options available through our weight loss service.

Monitoring and Follow-Up

Effective weight management with Wegovy requires ongoing monitoring of your progress, tolerance, and overall health status. We recommend regular weight measurements, monitoring for side effects (particularly during dose escalation), and periodic review of cardiovascular risk factors with your GP. If you do not achieve at least 5% weight loss after 12 weeks on the maintenance dose, NICE guidance suggests discontinuing therapy and exploring alternative strategies. Our pharmacy team provides ongoing support throughout your treatment journey and can facilitate prescriber reviews as needed.

Scientific References

1. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
2. Davies, M., Færch, L., Jeppesen, O. K., et al. (2021). Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet, 397(10278), 971–984. https://doi.org/10.1016/S0140-6736(21)00213-0 [accessed 13 August 2026]
3. Electronic Medicines Compendium. (2023). Wegovy 2.4 mg solution for injection in pre-filled pen - Summary of Product Characteristics (SmPC). Retrieved from https://www.medicines.org.uk/emc/product/13799/smpc [accessed 13 August 2026]
4. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
5. Sjöström, L., Rissanen, A., Andersen, T., et al. (1998). Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. The Lancet, 352(9123), 167–172. https://doi.org/10.1016/S0140-6736(97)11509-4 [accessed 13 August 2026]
6. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
7. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
8. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Individual results may vary. Weight loss outcomes depend on adherence to prescribed treatment and lifestyle modifications.